FLI1 and Ewing sarcoma: Our prior results showed that treatment with the noncompetitive LSD1 inhibitor, SP-2509, reverses the transcriptional activity of both EWSR1::FLI1 and EWSR1::ERG in Ewing sarcoma (18).